Answers are grounded in this paper and cite their sources.
Response to ranibizumab treatment for DME appears to be associated with aqueous concentrations of VEGFR1 family and certain inflammatory cytokines, but not with clinical parameters.
No takes yet. Share an insight, caveat, or question.
Shimura et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: